P-48: Ultrastructural and L.Microscopic Study of GnRH Potential in Inhibition of Side Effect of Drugs Used In Chemoterapy on Sertoli Cells

Background: Male factors, mainly spermatogenesis disorder, are responsible for 20 – 30% of infertility ocuurs in different societies. One of the known causes of spermatogenesis disorder is chemotherapy in patients with cancer. The side effect of chemoterpic agents may last from 10 years up to the end of the life. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH antagonist as a suppressor of spermatognial proliferation, on spermatogenic defect produced by anticancer drug (thiotepa). Materials and Methods: In the present study 30 adult male mice aging 6-8 weeks were uscd. The mice were divided into 3 equal groups as; control, thiotcpa (T group) and thiotepa + cetrorelix, a GnRH antagonist, (T +C group). Thiotcpa was injectctcd as ip for 5 days at 2.5 mg/kg doses. In T + C group cetrorelix injection was started one week before thiotepa treatment and continued for 3 more weeks. Since spermatogenic cycle in mice is 35 days, mice in all groups were sacrificed 35 days after thiotepa injection. Half of testicular specimens were fixed in boueins for LM studies and others were fixed in 2% glutaraldehyde and prepared for EM studies. The thin sections were studied with LEO 906 TEM. Results: Electron microscopic study showed that in control group sertoli cells had euchromatic nucleus with obvious nucleolus that usually showed one or two invagination in it and their cytoplasm lie on BL and there is BTB between them. In T group study showed that there were large spaces between sertoli and BL and also there were vacuoles in and between sertoli cells. Blood testis barrier were so irregular. In T + C group sertoli cells were similar to control group. Study of seminiferous with LM also show that mean of sertoli cells in control group were 13 ± 2.08 µm, in T group were 19.14 ± 3.67 µm and in T + C group were 12.85 ± 1.32 µm . Statistical Analysis of data show significance difference between control and T group (p<0.05) but not between control and T + C group (p<0.05). Conclusion: According to the result it is concluded that GnRH antagonist administration before cancer treatment could prevent the side effect of anticancer drugs.